LENZ Therapeutics
LENZ
67 hedge funds and large institutions have $75.8M invested in LENZ Therapeutics in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 11 closing their positions.
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
2% more funds holding
Funds holding: 66 → 67 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.15% less ownership
Funds ownership: 7.68% → 7.53% (-0.15%)
7% less capital invested
Capital invested by funds: $81.2M → $75.8M (-$5.47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$1.35M |
| 2 |
BlackRock
New York
|
+$235K |
| 3 |
Morgan Stanley
New York
|
+$184K |
| 4 |
Millennium Management
New York
|
+$147K |
| 5 |
CCM
Corsair Capital Management
New York
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.06M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$900K |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$596K |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$519K |
| 5 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$455K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Simplex Trading
Chicago,
Illinois
| – | +$470 | +27 | New |
|
LENZ Hedge Fund Activity: Q3 2023 in Review
67 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q3 2023, worth a combined $75.8M — down 6.7% from $81.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new LENZ positions and 11 closed out — a net gain of 1 holder — while 22 added to existing stakes and 17 trimmed.
The largest buyer was Newtyn Management, opening a new position worth an estimated $1.35M. The largest seller was Federated Hermes, exiting entirely with an estimated $1.06M sold.
- 67 institutional investors held LENZ Therapeutics (LENZ) as of Q3 2023, up from 66 in Q2 2023.
- Funds reported $75.8M of LENZ Therapeutics stock for Q3 2023, down 6.7% quarter-over-quarter.
- 12 funds opened new LENZ Therapeutics positions in Q3 2023 and 11 closed out, a net change of +1 holder.
- The largest LENZ Therapeutics buyer in Q3 2023 was Newtyn Management, an estimated $1.35M added.
- The largest LENZ Therapeutics seller in Q3 2023 was Federated Hermes, an estimated $1.06M sold.
Based on aggregated 13F filings for Q3 2023.